Compare FCCO & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCCO | TENX |
|---|---|---|
| Founded | 1994 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 317.8M |
| IPO Year | 2012 | 2001 |
| Metric | FCCO | TENX |
|---|---|---|
| Price | $30.07 | $11.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 61.4K | ★ 545.5K |
| Earning Date | 04-22-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 36.46 | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $922,000.00 | N/A |
| Revenue This Year | $30.67 | N/A |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $51.02 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.80 | $5.34 |
| 52 Week High | $31.51 | $18.38 |
| Indicator | FCCO | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 43.07 |
| Support Level | $29.16 | $10.87 |
| Resistance Level | $31.21 | $12.75 |
| Average True Range (ATR) | 0.67 | 0.67 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 56.64 | 51.11 |
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.